POTOMAC, MD — October 7, 2025 — Leads & Copy — IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s disease, has announced in-vitro findings for IGC-1C, a low-molecular weight compound, showing it acts as a modulator of the tau protein’s liquid-liquid phase separation (LLPS). The LLPS pathway represents a potential paradigm shift in neurodegenerative research, with IGC-1C offering the potential to halt disease progression before irreversible damage occurs.
According to Ram Mukunda, CEO of IGC Pharma, intervening at the phase separation stage could prevent the formation of toxic tau aggregates, opening a novel and scalable pathway to halt disease progression.
Preclinical experimental findings suggest IGC-1C’s mechanism of action and demonstrate powerful efficacy markers including inhibition and dissolution observed. IGC-1C was shown to inhibit the formation of zinc-mediated tau condensates and promote their dissolution. IGC-1C also demonstrated a strong binding affinity to tau, exhibiting a dissociation constant with tau of (Kd) 3.95 ± 0.32 μM. Microscopy and fluorescence assays demonstrated that IGC-1C reduces both the size and number of tau-zinc condensates and reduced their conversion into toxic amyloid fibrils. In neuroblastoma (SH-SY5Y) cell cultures, IGC-1C was well tolerated and permeable, confirming cellular compatibility.
IGC Pharma intends to move forward with additional validation studies in animal models, with the long-term goal of accelerating this candidate toward clinical trials.
Rosalyn Christian / John Nesbett
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200
Source: IGC Pharma
